This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other upper respiratory disease
  • /
  • Cromolyn-crosslinked chitosan nanoparticles for th...

Cromolyn-crosslinked chitosan nanoparticles for the treatment of allergic rhinitis.

Read time: 1 mins
Published:13th Feb 2019
Author: Abruzzo A, Cerchiara T, Bigucci F, Zuccheri G, Cavallari C, Saladini B et al.
Availability: Pay for access, or by subscription
Ref.:Eur J Pharm Sci. 2019 ;131:136-145.

The aim of this work was to prepare new mucoadhesive nasal decongestant nanoparticles obtained by direct crosslinking between the cationic polymer chitosan and the anionic drug cromolyn. Different chitosan/cromolyn molar ratios were used in order to obtain nanoparticles of suitable size, encapsulation efficiency/drug loading and mucoadhesion.

Moreover, the ability of the nanoparticles to deliver cromolyn into and through the nasal mucosa was evaluated. The obtained positively charged nanoparticles, sized 180-400 nm, showed interesting properties in terms of yield, mucoadhesion, encapsulation efficiency and drug loading. Release and permeation/penetration data indicated the ability of the nanoparticles to retain a high amount of cromolyn inside the mucosa, which is rich in mast cells. These findings suggest developing decongestant nanoparticles for potential treatment of allergic rhinitis.


Read abstract on library site

Access full article